The optimal antithrombotic therapy remains unknown for patients on chronic OAC following PCI with coronary stenting. (N)OAC and DAPT are currently recommended by the ESC guidelines, but are associated with increased risk of bleeding. Some studies have shown evidence that clopidogrel plus OAC may be an alternative for TT. In addition, NOACs may be as effective as VKA as part of TT or dual therapy. Currently, P2Y12 inhibitors (ticagrelor and prasugrel) are not recommended as part of TT in AF patients after PCI. Further research in RCTs are required to clarify the optimal antithrombotic regimen for patients on long-term (N)OAC following PCI.